PPP2R2A and metastatic neoplasm: Homozygous loss (deep deletion) of PPP2R2A in prostate adenocarcinomas was less common (15%; TCGA), particularly in datasets reporting metastatic tumors (<5%; SU2C) (Fig. 1a).